Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Annsa C. Huang"'
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
The United Network for Organ Sharing (UNOS) grants priority listing for liver transplant for patients with hepatocellular carcinoma after successful down-staging to Milan criteria. We evaluated the national experience on down-staging by comparing 2 d
Publikováno v:
Current Hepatology Reports. 19:186-196
The safety of non-selective beta-blockers (NSBB) in decompensated cirrhosis, particularly in patients with refractory ascites, has recently been called int question. This review summarizes recent evidence on the role of NSBBs in decompensated cirrhos
Autor:
Nghiem B. Ha, Annsa C. Huang, Jin Ge, Danielle Brandman, Courtney B. Sherman, Alexis M. Bayudan
Publikováno v:
American Journal of Gastroenterology. 116:S566-S567
Autor:
Andre Gorgen, Norah A. Terrault, Bettina E. Hansen, Les Lilly, Angel Rubin, Joanne M O'Rourke, Nazia Selzner, Annsa C. Huang, Carmen Vinaixa, Tahir Shah, Zita Galvin, François Durand, Neil Mehta, Marina Berenguer, Gonzalo Sapisochin, David Calatayud, Claire Francoz, Ahmed M. El-Sharkawy
Publikováno v:
Transplantation. 104(10)
BACKGROUND There is a lack of data on the use of direct-acting antivirals (DAA) on the risk of death and tumoral recurrence in patients with hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) listed for liver transplantation (LT). We aimed to
Autor:
Connie W. Wang, Annsa C. Huang, Jin Ge, Danielle Brandman, Courtney B. Sherman, Nghiem B. Ha, Jessica B. Rubin
Publikováno v:
American Journal of Gastroenterology. 115:S613-S614
Autor:
David A. Leiman, Annsa C. Huang, Priya Kathpalia, Justin Zhuo, Emily L. Romanoff, Afrin Kamal, Deron Amador, Fouad Otaki
Publikováno v:
Gastroenterology. 160:S-644
Publikováno v:
Gastroenterology. 158:S-1302
Publikováno v:
Hepatology (Baltimore, Md.), vol 68, iss 2
Whether direct-acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC) recurrence after tumor-directed therapy is controversial. We sought to determine the impact of DAA therapy on HCC recurrence after local-regional therapy (LRT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e36896d1c6240f9a0add857faee06017
https://europepmc.org/articles/PMC6097892/
https://europepmc.org/articles/PMC6097892/